Shots:
- The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US
- The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21, that explores the potential use in patients outside of the hospital setting. Additionally, AT-527 may be developed for post-exposure prophylactic settings
- AT-527 is an investigational, oral, purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus, including human flavivirus and coronavirus
Click here to read full press release/ article | Ref: Roche | Image: The Times of Israel
The post Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19 first appeared on PharmaShots.
